Despite the remarkable success of retinoid acid (RA) and arsenic trioxide (As2O3) combinational treatment over the course of APL research, rare RARα fusion proteins exhibit distinct mechanism and diverse drug responses. Here, RARA is linked to acute promyelocytic leukemia.